From breakthrough to bedside: ICPC pushes for global equity in precision oncology

The International Cancer Patient Coalition (ICPC) will host its landmark 2025 Working Meeting, From Global Declarations to Practical Delivery, on 30-31 May at Chicago’s Schreiber Center. This, invitation-only summit brings together global cancer leaders to confront the systemic gaps that prevent patients from accessing lifesaving precision oncology innovations.

Despite transformative tools like HER2-low therapies, ctDNA-guided trials, and radioligand theranostics, over half of eligible patients are still left behind due to diagnostic inconsistencies, reimbursement delays, and infrastructure barriers.

The global precision gap: What’s at stake

• 30–50% HER2-low diagnostic variability blocks access to antibody-drug conjugates (WHO 2024)
• 14-month delays in NSCLC resistance testing strand patients without next-line therapy (JCO Global Oncology 2025)
• 80% of hospitals lack MRD testing, despite 42% trial cost savings via decentralized models (Nature Medicine 2024)

From policy declarations to practical delivery

Across six action-driven sessions, attendees will co-design real-world strategies to:

• Standardize HER2-low testing through lab certification
• Eliminate NSCLC drug delays with pipeline reimbursement models
• Expand MRD access in LMICs via mobile units and outcomes-based pricing
• Scale radioligand therapy with new radiopharmacy hubs and regulatory reform

Please view full agenda.

Global experts driving change

The meeting brings together world-renowned experts whose work is shaping the future of precision oncology access:

Advancing diagnostic standards and equity

• Dr. Hesham Elghazaly – Professor of Clinical Oncology, Ain Shams University (Egypt): Championing HER2-low testing standards in emerging health systems
• Dr. Janice Tsang – Consultant Oncologist, HKCTS & ESMO Faculty Member (Hong Kong): Driving diagnostic equity across Asia-Pacific cancer networks

Transforming Access Through Policy & Innovation

• Lee-Anne Zinetti – Executive Director, Global Oncology Portfolio Precision Medicine Strategy, Novartis (Switzerland): Shaping trial access through ctDNA integration and biomarker-driven strategies
• Luciana Holtz – Founder & President, Oncoguia (Brazil): Leading patient-centered reforms in access and reimbursement across Latin America

Scaling Theranostics & MRD Integration

• Dr. Ken Herrmann – Chair of Nuclear Medicine, Universitätsklinikum Essen (Germany): Setting infrastructure and regulatory benchmarks for radioligand therapy scale-up
• Dr. Vivek Subbiah – Chief, Early-Phase Drug Development, Sarah Cannon Research Institute (USA): Defining global MRD evidence frameworks for early detection and treatment optimization

Who Should Attend

• Policymakers shaping next-generation reimbursement frameworks
• Clinicians scaling tumor-agnostic and resistance-informed care
• Advocates prioritizing rural and LMIC equity
• Industry leaders building sustainable innovation access pathways

Register now: Seats are limited for this closed-door working meeting focused on transforming innovation into equitable care delivery. Please register here.

About ICPC: The International Cancer Patient Coalition is a global alliance accelerating equitable access to cancer innovations. From synthetic data to screening equity, ICPC delivers policy action where patients need it most. (www.unite4cancer.com)

-- 

Dr. Denis Horgan, PhD, LLM, MSc, BCL
EAPM Executive Director,
Chair, ICGC ARGO Independent Advisory Committee 
International Cancer Genome Consortium
EAPM, Avenue de l'Armee/ Legerlaan 10,
1040 Brussels, BelgiumT: + 386 30 607 281
Website: www.euapm.eu

About EAPM

The European Alliance for Personalised Medicine brings together Europe's leading healthcare experts and patient advocates to improve patient care by accelerating the development, delivery and uptake of personalised medicine and diagnostics.

It is calling for the European Commission, the European Parliament and EU member states to help improve the regulatory environment so that patients can have early access to personalised medicine, and so that research is boosted.

Share this article: